Last updated: January 24, 2024
Sponsor: Second Affiliated Hospital of Soochow University
Overall Status: Active - Recruiting
Phase
4
Condition
N/ATreatment
levodopa/carbidopa/entacapone
Clinical Study ID
NCT06236230
JD-LK2023062-IR01
Ages 30-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Male or female and greater from 30 to 80.
- Diagnosis of idiopathic PD according to the MDS PD Diagnostic Criteria (2015).
- Hoehn-Yahr stage of 1.5-3.0 ("open" stage).
- Not on anti-PD medication or stable on anti-PD medication for at least 30 days.
Exclusion
Exclusion Criteria:
- Diagnosis of atypical Parkinsonian syndrome, vascular Parkinsonism or drug-inducedParkinsonism.
- History of surgery within 6 months.
- Alcoholism, drug abuse, or severe cognitive impairment (including severe Alzheimer'sdisease)
- Psychiatric illness, epilepsy, pregnancy and breastfeeding, and clinically significantconcomitant illnesses
- Participation in another clinical trial within 2 months.
- With dyskinesia.
- Any other condition that, in the opinion of the investigator, makes them ineligiblefor enrolment.
Study Design
Total Participants: 60
Treatment Group(s): 1
Primary Treatment: levodopa/carbidopa/entacapone
Phase: 4
Study Start date:
November 15, 2023
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
The Second Affiliated Hospital of Soochow University
Shanghai, Shanghai 2I5004
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.